How is ceftobiprole used in Canada: the CLEAR study final results

ABSTRACT

Background

We report the final results of the clinical usage of ceftobiprole in patients in Canada from data in the national CLEAR (Canadian Le adership on Antimicrobial Real-Life Usage) registry.

Research design and methods

The authors review the final data using the national ethics approved CLEAR study. Thereafter, the literature is surveyed regarding the usage of ceftobiprole to treat patients with infectious diseases via PubMed (up to March 2024).

Results

In Canada, ceftobiprole is primarily used as directed therapy to treat a variety of severe infections caused by MRSA. It is primarily used in patients failing previous antimicrobials, is frequently added to daptomycin and/or vancomycin with high microbiological and clinical cure rates, along with an excellent safety profile. Several reports attest to the microbiological/clinical efficacy and safety of ceftobiprole. Ceftobiprole is also reported to be used empirically in select patients with community-acquired bacterial pneumonia (CABP), as well as hospital-acquired bacterial pneumonia (HABP).

Conclusions

In Canada, ceftobiprole is used mostly as directed therapy to treat a variety of severe infections caused by MRSA, in patients failing previous antimicrobials. It is frequently added to, and thus used in combination with daptomycin and/or vancomycin with high microbiological/clinical cure rates, and an excellent safety profile.

KEYWORDS:

• Ceftobiprole
• cephalosporins
• MRSA infections
• endocarditis
• bacteremia
• pneumonia

Article highlights

• Clinical usage data of ceftobiprole are limited.

• We report the final results of ceftobiprole usage in patients in Canada using data captured by the national CLEAR registry.

• Of the first 100 patients reported, the most common infections treated with ceftobiprole were endocarditis, bone/joint infection, and hospital-acquired bacterial pneumonia (HABP) with almost all patients having a concomitant bacteremia.

• Ceftobiprole was primarily used as directed therapy for methicillin-resistant Staphylococcus aureus (MRSA) infections and added to failing vancomycin and/or daptomycin regimens.

• Ceftobiprole usage was associated with high rates of microbiological and clinical success along with a good safety profile.

• In Canada to date, ceftobiprole is used as directed therapy to treat a variety of severe infections caused by MRSA.

• Outside of Canada, ceftobiprole is used as directed therapy and empirically in select patients with a variety of infections, especially community-acquired bacterial pneumonia (CABP) and HABP as part of treatment algorithms.

Declaration of interest

GG Zhanel has received research funding from Avir, Iterum, Merck & Co, Paladin labs, Pfizer Inc, Sandoz, Venatorx, Verity and Zambon. C Tascini has received research funding from, Merck & Co, Pfizer Inc, Zambon, Advanz, Infectopharm, Biotest, Hikma, Menarini, Gilead, Viatris, Diasorin, and Thermofisher. The other authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

All authors contributed in the conception, study design, execution, acquisition of data, analysis and interpretation. In addition, all authors were involved in drafting, revising the article and agreed on the journal to which the article was submitted. All authors, reviewed and agreed on all versions of the article before submission, during revision, the final version accepted for publication, and any significant changes introduced at the proofing stage. Lastly all authors take responsibility and be accountable for the contents of the article and to share responsibility to resolve any questions raised about the accuracy or integrity of the published work.

Additional information

Funding

This paper was not funded.